Regulatory Approval

AstraZeneca PLC
5 June 2002





                   ASTRAZENECA RECEIVES FDA 'APPROVABLE' LETTER

                                 FOR CRESTOR(TM)





AstraZeneca today confirms that it has received an 'approvable' letter from the
U.S. Food and Drug Administration (FDA) in response to its New Drug Application
(NDA) for 'Crestor' (rosuvastatin).  The Company is reviewing its contents, and
has no further comment at this time.





                                     -Ends-

June 5, 2002



Media Enquiries:
Emily Denney, Tel: [phone]



Investor Relations:
Jonathan Hunt, Tel:  [phone]






                      This information is provided by RNS
            The company news service from the London Stock Exchange
                IEIIF